author-photo

Natalie Hoog Labouret

18

Papers

70

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Nivolumab in metastatic nonclear cell renal cell carcinoma: First results of the AcSe prospective study.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Vemurafenib in Advanced Patients with Hairy Cell Leukemia (HCL): Results of the Acsé Phase II Trial

2017 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Crizotinib in Advanced ALK+ Anaplastic Large Cell Lymphoma in Children and Adults: Results of the Acs© Phase II Trial

2017 Blood
Show All
- Source
- Cite
- Save
Citations (3)
P3.02a-034 Vemurafenib in Patients with Non-Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial: Topic: Miscellaneous

2017 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSé phase II trial.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Biomarker-driven access to vemurafenib in BRAF-positive cancers: Second study of the French National AcSé Program.

2016 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
Conséquences des traitements des cancers et préservation de la fertilité

2013 Oncologie
- Natalie Hoog Labouret
- Françoise Merlet
Show All
- Source
- Cite
- Save
Citations (5)
Consequences of cancer treatments and fertility preservation: Report and propositions

2013
- Natalie Hoog Labouret
- Françoise Merlet
Show All
- Source
- Cite
- Save
Citations (0)
Clinical Trials in Children: Guidance Ich Ell

2006
- Natalie Hoog Labouret
Show All
- Source
- Cite
- Save
Citations (2)